Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
---|---|
Information provided by: | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
ClinicalTrials.gov Identifier: | NCT00129246 |
This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain.
Condition | Intervention | Phase |
---|---|---|
Smoking Nicotine Dependence |
Drug: Naltrexone Drug: Bupropion |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Naltrexone & Bupropion to Stop Smoking With Less Weight Gain |
Estimated Enrollment: | 20 |
Study Start Date: | December 2004 |
Study Completion Date: | December 2005 |
This is an open label smoking cessation clinical trial of 25 mg naltrexone with 300 mg bupropion sustained-release (SR) in six male and fourteen female participants. This pilot study is being conducted to determine:
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Connecticut | |
Yale University School of Medicine Substance Abuse Treatment Unit | |
New Haven, Connecticut, United States, 06511 |
Principal Investigator: | Benjamin Toll, Ph.D. | Yale University School of Medicine Department of Psychiatry |
Study ID Numbers: | NIAAAOMA15632-B, NIH Grant 9 P50-AA15632 |
Study First Received: | August 9, 2005 |
Last Updated: | November 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00129246 |
Health Authority: | United States: Federal Government |
Tobacco Smoking Weight |
Weight perception Naltrexone Bupropion |
Body Weight Signs and Symptoms Smoking Dopamine Mental Disorders Tobacco Use Disorder |
Naltrexone Bupropion Body Weight Changes Substance-Related Disorders Disorders of Environmental Origin Weight Gain |
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Narcotic Antagonists Physiological Effects of Drugs Psychotropic Drugs Pharmacologic Actions |
Habits Sensory System Agents Therapeutic Uses Dopamine Agents Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |